Company overview

Organogenesis Holdings Inc. supplies products that clinicians use to treat chronic and acute wounds, including Apligraf, PuraPly AM and NuShield. Advanced wound care generates the vast majority of its product revenue; a smaller business supplies products for surgical wounds and tendon and ligament injuries. Hospitals, wound care centers and physician offices buy its products, including products it licenses from other companies.

Those purchases depend heavily on whether Medicare, Medicaid and private insurers cover treatment and pay enough to support product use. Most private insurers cover Apligraf but provide limited coverage for PuraPly AM and NuShield. Medicare now pays separately for non-BLA skin substitutes as supplies used with covered procedures at a common reimbursement rate across care settings. Physician adoption and payer coverage therefore shape demand, not just the need for wound treatment.

Many products require donated human tissue, and the company relies on a limited group of suppliers and manufacturers. FDA rules also constrain what it can sell and how products may be used. Certain tissue products can avoid premarket approval only if their processing and intended use meet specific requirements; NuShield, for example, is labeled as a protective barrier. If the FDA finds those requirements unmet, it could require approval before further sales.